Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 776 - 800 of 895 in total
Experimental
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
The use of the plant species Cannabis sativa and Cannabis indica, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America has changed public and medical opinion on its use. Consequently, an...
Experimental
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inducers (strength unknown) ... Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inducers (strength unknown) …
Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet...
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Black cohosh (Actaea racemosa or Cimicifuga racemosa), a member of the buttercup family, is a perennial plant which native to North America. Historical names for this plant include snakeroot, black bugbane, rattleweed, macrotys, and rheumatism weed. Black cohosh has a long history of use. Native Americans used it for its...
Experimental
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2A6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as...
Experimental
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP) is a synthetic analogue of meperidine. It is sold as a "synthetic heroin."
Experimental
Illicit
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Nabiximols (tradename Sativex®) is a whole plant extract from the Cannabis species Cannabis sativa L. that has been purified into the active components CBD (cannabidiol) and THC (delta-9-tetrahydrocannabinol). For trademark purposes, purified CBD is branded as Nabidiolex®, while THC is purified as the product Tetrabinex®. Sativex® is available in a...
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Fluprednidene acetate is a corticosteroid. It has anti-inflammatory and anti-allergic properties.
Experimental
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A5 Inhibitors (strength unknown) ... Cytochrome P-450 CYP3A7 Inhibitors (strength unknown) …
Experimental
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
A 6-methyl progesterone acetate with reported glucocorticoid activity and effect on estrus.
Experimental
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Experimental
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Experimental
Matched Categories: … Cytochrome P-450 CYP3A4 Inducers (strength unknown) ... Cytochrome P-450 CYP3A5 Inducers (strength unknown) …
Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to regenerate adenosine triphosphate (ATP) from...
Nutraceutical
GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves. GPI 1485 is being studied in phase 2 clinical trials for the treatment...
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) …
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Benzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
Investigational
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood...
Experimental
Matched Categories: … Cytochrome P-450 CYP2C19 inhibitors (strength unknown) ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Displaying drugs 776 - 800 of 895 in total